Short answer
Evolent Health, Inc. (EVH) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing text contains only standard forward-looking-statement safe-harbor language.
Evolent Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing text contains only standard forward-looking-statement safe-harbor language
- No fiscal 2026 operating results or financial metrics disclosed
- Investors should review the referenced exhibit for substantive earnings information
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $652.5M, up from $444.3M; GAAP net loss narrowed to $28.4M from $51.1M
- Adjusted EBITDA $28.1M, down from $37.5M; margin compressed to 4.3% from 8.5%
- Medical expense ratio rose to 95.3% from 80.0%, signaling significant pressure on Performance Suite profitability
- 2026 guidance raised to $2.6–$2.7B revenue and tightened to $120–$135M Adjusted EBITDA
- Oncology launch targeted by December 2026 across approximately 1.5M lives, with approximately $300M annualized revenue potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Evolent Health, Inc. 8-K filings
Get the next EVH 8-K as it lands
Follow EVH for push alerts, or ask the research agent what this filing means.